WO2015060736A3 - The use of egfr and hgfr agonists as anticancer drugs acting on tumour cells of certain phenotype - Google Patents
The use of egfr and hgfr agonists as anticancer drugs acting on tumour cells of certain phenotype Download PDFInfo
- Publication number
- WO2015060736A3 WO2015060736A3 PCT/PL2014/000115 PL2014000115W WO2015060736A3 WO 2015060736 A3 WO2015060736 A3 WO 2015060736A3 PL 2014000115 W PL2014000115 W PL 2014000115W WO 2015060736 A3 WO2015060736 A3 WO 2015060736A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- egfr
- hgfr
- agonists
- mutakthet
- mutant
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 4
- 108060006698 EGF receptor Proteins 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 229940041181 antineoplastic drug Drugs 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 title 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 8
- 230000003217 anti-cancerogenic effect Effects 0.000 abstract 5
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 abstract 4
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 abstract 4
- 230000003213 activating effect Effects 0.000 abstract 2
- 230000014509 gene expression Effects 0.000 abstract 2
- 238000005734 heterodimerization reaction Methods 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 2
- 230000002018 overexpression Effects 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Current opinion is that anti-carcinogenic effects related to receptors such as EGFR or HGFR (MET) and their mutants may be achieved by means of blocking them. Though, there are situations in which anti-carcinogenic therapy may be based on activation of these receptors. Condition, under which the EGFR agonists exert their anti-carcinogenic effects is that cells treated with them should present high expression levels of activating heterodimerization-inducing EGFR mutant (EGFRMUTaktHET) and EGFRwt. Similarly, high expression level of HGFR and the activating heterodimerization-inducing EGFR mutant is possible. Anti-carcinogenic effects of EGFR agonists are also possible in cells showing over-expression of EGFR only, without increased level of the EGFR mutant (EGFRMUTaktHET), as well as anti-carcinogenic effects of HGFR agonists can be observed in cells showing over-expression of HGFR only, without increased level of the EGFR mutant (EGFRMUTaktHET).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PLPL405768 | 2013-10-24 | ||
| PL40576813A PL405768A1 (en) | 2013-10-24 | 2013-10-24 | Application of EGFR and HGFR agonists as anticancer drugs, acting on cancer cells with specified phenotype |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2015060736A2 WO2015060736A2 (en) | 2015-04-30 |
| WO2015060736A3 true WO2015060736A3 (en) | 2015-07-30 |
Family
ID=51999483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/PL2014/000115 WO2015060736A2 (en) | 2013-10-24 | 2014-10-23 | The use of egfr and hgfr agonists as anticancer drugs acting on tumour cells of certain phenotype |
Country Status (2)
| Country | Link |
|---|---|
| PL (1) | PL405768A1 (en) |
| WO (1) | WO2015060736A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111254117B (en) * | 2018-11-30 | 2022-05-31 | 中国科学院大连化学物理研究所 | Mutant EGFR high-expression recombinant MHCC97-L liver cancer cell and construction |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001009186A2 (en) * | 1999-07-30 | 2001-02-08 | Medarex, Inc. | Therapeutic compounds comprised of anti-fc receptor binding agents |
| WO2006038880A1 (en) * | 2004-10-08 | 2006-04-13 | Damavand'wound Ab | New composition and method |
-
2013
- 2013-10-24 PL PL40576813A patent/PL405768A1/en unknown
-
2014
- 2014-10-23 WO PCT/PL2014/000115 patent/WO2015060736A2/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001009186A2 (en) * | 1999-07-30 | 2001-02-08 | Medarex, Inc. | Therapeutic compounds comprised of anti-fc receptor binding agents |
| WO2006038880A1 (en) * | 2004-10-08 | 2006-04-13 | Damavand'wound Ab | New composition and method |
Non-Patent Citations (2)
| Title |
|---|
| D. W. BARNES: "Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture", THE JOURNAL OF CELL BIOLOGY, vol. 93, no. 1, 1 April 1982 (1982-04-01), pages 1 - 4, XP055181212, ISSN: 0021-9525, DOI: 10.1083/jcb.93.1.1 * |
| JOHNS TERRANCE G ET AL: "The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 6, 15 March 2007 (2007-03-15), pages 1911 - 1925, XP002614294, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-06-1453 * |
Also Published As
| Publication number | Publication date |
|---|---|
| PL405768A1 (en) | 2015-04-27 |
| WO2015060736A2 (en) | 2015-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016013635A (en) | Methods for increasing red blood cell levels and treating sickle-cell disease. | |
| CA2956871C (en) | Compounds active towards bromodomains | |
| CA2909335C (en) | Fenfluramine for use in the treatment of dravet syndrome | |
| MX2020010412A (en) | Inhibitors of bruton's tyrosine kinase. | |
| MX2017007321A (en) | Combination therapies. | |
| PE20150223A1 (en) | ANTIBODIES ENHANCED ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR-8 AND THE USES OF THEM | |
| WO2015073587A3 (en) | Synthetic membrane-receiver complexes | |
| AU2018341571A8 (en) | Therapeutic methods relating to HSP90 inhibitors | |
| WO2015002724A3 (en) | SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | |
| CA2900335C (en) | Synthetic analogs of epipolythiodioxopiperazines and uses thereof | |
| WO2014144847A3 (en) | Hspc-sparing treatments for rb-positive abnormal cellular proliferation | |
| MX2015009105A (en) | Solid solution compositions and use in chronic inflammation. | |
| SG10201808835QA (en) | Anti-siglec-8 antibodies and methods of use thereof | |
| MX2015012922A (en) | Cancer treatment using antibodies that bing cell surface grp78. | |
| MX2015008241A (en) | Methods of treating gastrointestinal spasms. | |
| EP4218809A3 (en) | Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers | |
| MX2019010852A (en) | Lipid-based nanoparticles with enhanced stability. | |
| WO2016160621A3 (en) | Nk-92 cells in combination therapy with cancer drugs | |
| BR112017021700A2 (en) | Therapeutic compositions and methods of use for cancer treatment | |
| MX2020002852A (en) | Improved treatment of atopic dermatitis with tradipitant. | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| PH12015501282B1 (en) | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms | |
| MX2023009370A (en) | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy. | |
| MX2018000052A (en) | Compositions and methods for combination therapy with dengue virus and dendritic cells. | |
| AU2013208104A8 (en) | Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14805373 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14805373 Country of ref document: EP Kind code of ref document: A2 |